Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the pharmacokinetics, efficacy, and safety of subcutaneous fixed-dose combination of pertuzumab and trastuzumab with chemotherapy in H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Early Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-06-25